P&G Avobenzone Combo Data Demonstrate Broad Spectrum Protection - FDA
This article was originally published in The Tan Sheet
Executive Summary
The combinations of avobenzone and either zinc oxide or phenylbenzimidazole sulfonic acid (PBSA) are safe and effective for use in sunscreens "when used in the concentrations established for each ingredient" in the sunscreen final monograph, FDA tells Procter & Gamble in a Nov. 2 letter.
You may also be interested in...
Industry Groups Shine Light On “Helps Prevent” Claim In Sunscreen Comments
Sunscreen labeling that claims the product "helps prevent" premature skin aging, cancer and other damage does not suggest sunscreen alone protects against these conditions, but in fact informs consumers that "complementary measures" are needed for adequate protection, according to trade groups' comments on FDA's proposal to amend the sunscreen final monograph
Sunscreen Proposed Rule May Create UVA Protection Marketing Opportunity
FDA's proposed rule amending its final monograph on sunscreens to include UVA ray protection standards could create new marketing opportunities for manufacturers (see chart: "1Selected Proposed Changes To OTC Sunscreen Monograph")
P&G on UVA
Procter & Gamble submits additional UVA efficacy data supporting the addition of avobenzone combined with either 2-pherrylbenzimidazole-5 sulfonic acid (PBSA) or zinc oxide in the final sunscreen monograph. The in vivo data show 1.5% PBSA with 3% avobenzone had a protection factor of 3.6, versus 1.4 for PBSA alone. Similarly, 4% zinc oxide combined with 3% avobenzone had a 5.6 protection factor compared to 2.3 with zinc oxide alone. P&G originally submitted safety data on the ingredients after a Jan. 27 "feedback" meeting with the agency ("The Tan Sheet" March 15, In Brief). FDA found the data insufficient ("The Tan Sheet" April 26, p. 9)